In two different TMZ-naïve intracranial GBM patient-derived xenograft models, one displaying partial MGMT promoter methylation and the other displaying full MGMT promoter methylation, KL-50 displayed robust monotherapy activity compared to vehicle control, approximately doubling mouse median survival. Here, MGMT is linked to glioblastoma.